Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)

Dianthus Therapeutics has reported Accumulated Expenses for 9 years, with the latest figure at $19.5 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses rose 48.78% year-over-year to $19.5 million; the trailing twelve-month figure through Dec 2025 stood at $19.5 million (up 48.78% YoY), and the FY2025 full-year result was $19.5 million, up 48.78% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $19.5 million, up from $16.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $19.5 million in Q4 2025, with the low at $1.6 million in Q1 2023.
• Average Accumulated Expenses over 5 years is $8.5 million, with a median of $7.4 million recorded in 2021.
• Year-over-year, Accumulated Expenses slumped 75.55% in 2023 and jumped 273.13% in 2024.
• Tracing DNTH's Accumulated Expenses over 5 years: stood at $7.8 million in 2021, then decreased by 15.53% to $6.6 million in 2022, then dropped by 1.57% to $6.5 million in 2023, then jumped by 101.01% to $13.1 million in 2024, then soared by 48.78% to $19.5 million in 2025.
• The last three Accumulated Expenses figures came in at $19.5 million (Q4 2025), $16.0 million (Q3 2025), and $14.0 million (Q2 2025), per Business Quant data.

Peer Comparison